# cypA Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *PPIA* gene encodes cyclophilin A (CypA), a peptidyl-prolyl *cis-trans* isomerase (PPIase) and crucial host factor for viral replication, including HIV-1, HCV, and coronaviruses, by facilitating protein folding and viral assembly.
- CypA's canonical PPIase activity is essential for protein folding, but it also acts as a signaling hub, promoting NF-κB and JAK-STAT pathway activation, and its extracellular form, released via non-classical secretion, acts as a chemoattractant for leukocytes by binding the CD147 receptor.
- The immunosuppressive drug cyclosporine A (CsA) targets CypA, forming a complex with calcineurin that inhibits T-cell activation, while non-immunosuppressive analogs like alisporivir are being developed for antiviral therapies, particularly against HCV and HIV-1.
- Germline *PPIA* mutations are rare but can cause severe combined immunodeficiency-like phenotypes due to impaired PPIase activity or signaling roles, while somatic mutations and expression alterations are observed in various cancers, often correlating with poor prognosis.
- CypA's interaction with HIV-1 capsid protein is critical for viral uncoating, reverse transcription, and immune evasion from TRIM5α, and is a target for non-immunosuppressive cyclophilin inhibitors.

---

## Executive Summary & Key Metadata

The **cypA** gene encodes cyclophilin A (CypA), a ubiquitously expressed peptidyl-prolyl *cis-trans* isomerase (PPIase) that belongs to the cyclophilin family. CypA is a multifunctional protein involved in protein folding, intracellular trafficking, immune modulation, and signal transduction. Beyond its canonical chaperone activity, CypA is a critical host factor for multiple viral pathogens, including human immunodeficiency virus type 1 (HIV-1), hepatitis C virus (HCV), and coronaviruses. Its enzymatic active site is the target of the immunosuppressive drug cyclosporine A (CsA), which forms a ternary complex with CypA and calcineurin, blocking T-cell activation. CypA has also been implicated in cardiovascular disease, cancer progression, and neurodegenerative disorders. The protein is encoded by the *PPIA* gene (peptidylprolyl isomerase A) in humans; however, the symbol **cypA** is used across prokaryotic and eukaryotic orthologs, and in this reference manual, we focus on the human *PPIA* gene product while acknowledging the cross-species nomenclature.

| **Metadata Field** | **Value** |
|:-------------------|:----------|
| **HGNC Symbol** | PPIA (commonly referred to as cypA) |
| **UniProt Accession** | E5KIB6 (representative; canonical human: P62937) |
| **Representative PDB ID** | 1AWQ (human CypA with bound CsA); 1M9C (apo form) |
| **Chromosomal Locus** | 7p13 (human); GRCh38: chr7:44,796,681–44,803,082 (minus strand) |
| **Primary Molecular Function** | Peptidyl-prolyl cis-trans isomerase activity (EC 5.2.1.8); chaperone; HIV-1 capsid binding |
| **Disease & Pathology Associations** | HIV-1 infection (host factor), HCV replication, atherosclerosis, cancer (breast, lung, pancreatic), Alzheimer's disease, rheumatoid arthritis |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The human *PPIA* gene (cypA) is located on the short arm of chromosome 7 at cytogenetic band **7p13**. According to the GRCh38 assembly, the gene spans approximately 6.4 kilobases (kb) of genomic DNA, from position 44,796,681 to 44,803,082 on the minus strand. The gene contains **5 exons and 4 introns**, with the coding sequence (CDS) spanning 495 nucleotides, encoding a 165-amino-acid mature protein (after cleavage of the initiator methionine). The 5' untranslated region (UTR) is relatively short (~40 bp), while the 3' UTR is ~600 bp and contains multiple AU-rich elements (AREs) that regulate mRNA stability in response to cellular stress.

The promoter region of *PPIA* lacks a canonical TATA box but contains a GC-rich region with multiple Sp1 (specificity protein 1) binding sites. This promoter architecture is characteristic of housekeeping genes, consistent with the ubiquitous and constitutive expression of CypA across all tissues. However, expression levels are not static; the promoter contains functional response elements for **hypoxia-inducible factor 1-alpha (HIF-1α)**, **nuclear factor kappa B (NF-κB)**, and **p53**, allowing transcriptional upregulation under hypoxic, inflammatory, and genotoxic stress conditions. A polymorphic microsatellite repeat (CA)n located ~1.2 kb upstream of the transcription start site has been associated with differential promoter activity in some populations, though functional validation remains incomplete.

### 1.2 Enhancer Elements and Chromatin Architecture

Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from the ENCODE project reveal that the *PPIA* locus is embedded within a topologically associating domain (TAD) that includes the neighboring genes *SLC25A3* (mitochondrial phosphate carrier) and *ZNF12* (zinc finger protein 12). Active enhancer marks (H3K27ac and H3K4me1) are found in intron 1 and in a region ~3 kb downstream of the 3' UTR. These enhancers are bound by the transcription factors **GABPα** (GA-binding protein alpha) and **ELK1** (ETS domain-containing protein), which cooperate with Sp1 to maintain basal transcription. In T cells, the distal enhancer at +3 kb is additionally bound by **NFAT** (nuclear factor of activated T-cells), linking CypA expression to calcium-dependent signaling pathways.

### 1.3 Alternative Splicing and Isoforms

Although *PPIA* is a single-copy gene, alternative splicing generates at least three transcript variants:

1. **Transcript Variant 1 (canonical, NM_021130.5)**: Encodes the full-length 165-amino-acid CypA protein. This is the dominant isoform in all tissues and is the primary subject of this manual.
2. **Transcript Variant 2 (NM_001300981.2)**: Retains intron 3, introducing a premature stop codon. This transcript is a candidate for nonsense-mediated decay (NMD) and is expressed at very low levels. However, under cellular stress, this variant can escape NMD and produce a truncated 89-amino-acid protein lacking the C-terminal alpha-helix, which may act as a dominant-negative regulator of CypA dimerization.
3. **Transcript Variant 3 (NM_001300982.2)**: Uses an alternative 5' splice donor site in exon 1, resulting in a 12-amino-acid N-terminal extension. This isoform is enriched in testicular tissue and has been shown to localize preferentially to the nucleus, suggesting a role in chromatin remodeling.

Additionally, a **retroprocessed pseudogene** (PPIAP1) is located on chromosome 1q21.3. This pseudogene lacks introns and contains multiple frameshift mutations, rendering it non-functional. However, its promoter region has been co-opted as an enhancer for the neighboring *S100A7* gene in keratinocytes.

### 1.4 Post-Transcriptional Regulation

The 3' UTR of *PPIA* mRNA contains three AREs that are recognized by **AUF1** (AU-rich element RNA-binding protein 1) and **HuR** (human antigen R). Under normal conditions, AUF1 promotes mRNA decay, maintaining low basal CypA levels. Upon oxidative stress or viral infection, HuR translocates from the nucleus to the cytoplasm and stabilizes the mRNA, leading to a 3- to 5-fold increase in CypA protein within 2–4 hours. MicroRNA-mediated regulation has also been reported: **miR-124** and **miR-506** directly target the 3' UTR and downregulate CypA expression in neuronal and ovarian cancer cells, respectively. This post-transcriptional layer of regulation allows rapid CypA induction without requiring de novo transcription.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Fold and Domain Organization

CypA is a small, globular protein of 165 amino acids with a molecular weight of approximately 18 kDa. The three-dimensional structure, first solved by X-ray crystallography in 1991, reveals a compact **β-barrel fold** composed of eight antiparallel β-strands (β1–β8) that form a hydrophobic core, flanked by two α-helices (α1 and α2) and two short 3₁₀-helices. The overall topology is a classic **cyclophilin-like fold**, shared by all members of the cyclophilin family, including cyclophilin B, C, and D.

The domain architecture can be divided into three functional regions:

1. **N-terminal region (residues 1–40)**: Contains β-strands β1–β3 and the α1 helix. This region is not directly involved in catalysis but contributes to substrate recognition and mediates protein-protein interactions with the HIV-1 capsid (CA) protein. Residues **Arg55** and **Arg69** (located in the adjacent loop) form a positively charged patch that binds to the proline-rich loop of HIV-1 CA.

2. **Catalytic core (residues 41–140)**: Comprises β-strands β4–β8 and the α2 helix. The active site is a hydrophobic pocket formed by the side chains of **Phe60, Met61, Phe113, Leu122, and His126**. The catalytic mechanism relies on a single conserved residue, **Arg55**, which donates a hydrogen bond to the carbonyl oxygen of the proline residue in the substrate, lowering the energy barrier for *cis-trans* isomerization. The residue **His126** acts as a general base, abstracting a proton from the substrate's amide nitrogen to stabilize the transition state.

3. **C-terminal region (residues 141–165)**: Contains the α2 helix and a flexible tail. This region is essential for dimerization and for binding to the immunosuppressive drug cyclosporine A (CsA). The C-terminal tail also contains a nuclear export signal (NES) spanning residues 150–160, which mediates CRM1-dependent nuclear export.

### 2.2 Active Site Architecture and Catalytic Mechanism

The PPIase active site of CypA is a shallow, solvent-exposed groove on the surface of the β-barrel. The substrate specificity is determined by a preference for proline residues preceded by a hydrophobic or aromatic amino acid (e.g., -Ala-Pro-, -Phe-Pro-, -Leu-Pro-). The catalytic cycle proceeds via a **desolvation mechanism**:

1. **Substrate binding**: The proline residue of the substrate inserts into the hydrophobic pocket, with the preceding residue forming a hydrogen bond with the backbone carbonyl of **Asn102**.
2. **Transition state stabilization**: **Arg55** forms a bidentate hydrogen bond with the substrate's carbonyl oxygen, while **His126** protonates the amide nitrogen. This dual interaction distorts the peptide bond, reducing the rotational energy barrier from ~20 kcal/mol to ~5 kcal/mol.
3. **Isomerization**: The peptide bond rotates 180° around the C-N axis, converting the *cis* conformation to the *trans* conformation (or vice versa).
4. **Product release**: The isomerized substrate is released, and the enzyme returns to its ground state.

The catalytic efficiency (kcat/Km) of CypA is approximately 10⁶–10⁷ M⁻¹s⁻¹ for tetrapeptide substrates, making it one of the most efficient PPIases known. The enzyme is inhibited by cyclosporine A (CsA) with a Ki of ~6 nM, and by non-immunosuppressive CsA analogs such as **alisporivir** (Ki ~10 nM).

### 2.3 Post-Translational Modifications and Structural Dynamics

CypA is subject to several post-translational modifications that modulate its function:

- **Phosphorylation at Ser77**: This modification, mediated by **protein kinase C (PKC)**, enhances CypA's PPIase activity and promotes its secretion from cells. Phosphorylated CypA is found in the extracellular space, where it acts as a chemokine.
- **Acetylation at Lys125**: Acetylation by the acetyltransferase **p300** reduces PPIase activity but increases CypA's ability to bind HIV-1 CA, suggesting a switch between chaperone and viral restriction functions.
- **Oxidation of Cys52**: Under oxidative stress, Cys52 forms a disulfide bond with Cys62, inactivating the enzyme. This redox-sensitive regulation is thought to be a protective mechanism to prevent CypA-mediated inflammation during oxidative bursts.

Nuclear magnetic resonance (NMR) relaxation studies have revealed that CypA exhibits significant conformational dynamics on the microsecond-to-millisecond timescale, particularly in the loops surrounding the active site. These dynamics are essential for substrate promiscuity, allowing the enzyme to accommodate diverse proline-containing peptides. Binding of CsA or HIV-1 CA stabilizes a closed conformation, reducing backbone flexibility by ~30%.

### 2.4 Interactive 3D Visualization

For a hands-on exploration of the CypA structure, including the active site residues, CsA-binding pocket, and HIV-1 CA interaction surface, use the interactive visualizer:

[Interactive 3D Protein Visualizer: Load cypA (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=E5KIB6)

The visualizer supports multiple representations (cartoon, surface, sticks), residue highlighting, and distance measurements. Key residues to examine include Arg55, His126, Phe113, and the CsA-binding loop (residues 121–130).

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Canonical PPIase Activity and Protein Folding

The primary biochemical function of CypA is to catalyze the *cis-trans* isomerization of proline imidic peptide bonds in nascent polypeptides. This reaction is rate-limiting for the folding of many proteins, including collagens, histones, and ion channels. In the endoplasmic reticulum (ER), CypA cooperates with other chaperones (BiP, calnexin) to ensure proper folding of secreted and membrane proteins. In the cytosol, CypA associates with the ribosome-associated complex (RAC) and facilitates co-translational folding of newly synthesized proteins.

### 3.2 CypA as a Signaling Hub: The NF-κB and JAK-STAT Pathways

Beyond its chaperone function, CypA directly modulates several signaling cascades:

**NF-κB Pathway**: CypA binds to the p65 subunit of NF-κB and promotes its nuclear translocation. Mechanistically, CypA interacts with the nuclear import receptor **importin-β** and facilitates the transport of the p65-CypA complex through the nuclear pore complex. Knockdown of CypA in macrophages results in a 50–70% reduction in NF-κB-dependent gene expression following lipopolysaccharide (LPS) stimulation. This regulation is independent of PPIase activity, as a catalytically dead mutant (R55A) retains the ability to promote p65 nuclear import.

**JAK-STAT Pathway**: CypA interacts with **JAK2** and enhances its autophosphorylation, leading to increased STAT5 activation. This interaction is particularly important in hematopoietic cells, where CypA promotes erythropoietin (EPO)-dependent erythroid differentiation. Conversely, CypA overexpression in myeloproliferative neoplasms (e.g., JAK2-V617F-positive polycythemia vera) exacerbates constitutive STAT5 signaling, contributing to uncontrolled proliferation.

**MAPK/ERK Pathway**: In response to growth factor stimulation, CypA is phosphorylated by **ERK1/2** at Ser77. Phosphorylated CypA then translocates to the nucleus, where it binds to the promoter of *CCND1* (cyclin D1) and enhances its transcription. This nuclear function of CypA is critical for cell cycle progression and is exploited by cancer cells to sustain proliferation.

### 3.3 Extracellular CypA as a Cytokine

CypA is actively secreted from cells in response to inflammatory stimuli (LPS, TNF-α, oxidative stress) via a non-classical pathway involving **ABC transporters** and **exosomes**. Once in the extracellular space, CypA functions as a potent chemoattractant for neutrophils, eosinophils, and T cells. This activity is mediated by binding to the **CD147 receptor** (also known as basigin or EMMPRIN), which is expressed on the surface of leukocytes and endothelial cells. The CypA-CD147 interaction triggers a signaling cascade involving:

1. **ERK1/2 phosphorylation** → activation of matrix metalloproteinases (MMP-1, MMP-2, MMP-9)
2. **PI3K/Akt activation** → cell survival and migration
3. **Ca²⁺ mobilization** → chemotaxis

The extracellular CypA-CD147 axis is a major driver of inflammation in rheumatoid arthritis, atherosclerosis, and acute lung injury. Monoclonal antibodies targeting CD147 (e.g., **mepelizumab** analogs) are in clinical trials for these indications.

### 3.4 Protein-Protein Interaction Network

CypA participates in a dense interaction network, as catalogued by BioGRID and STRING databases. Key interaction partners include:

| **Partner** | **Function** | **Interaction Type** |
|:------------|:-------------|:---------------------|
| **HIV-1 CA** | Viral capsid assembly | Direct binding (Kd ~10 µM) |
| **CD147** | Extracellular signaling | Receptor-ligand |
| **Calcineurin (PPP3CA)** | T-cell activation | Ternary complex with CsA |
| **p53 (TP53)** | DNA damage response | Direct binding; inhibits p53 tetramerization |
| **Importin-β (KPNB1)** | Nuclear transport | Direct binding |
| **JAK2** | Cytokine signaling | Direct binding; enhances kinase activity |
| **TRAF6** | Innate immunity | Direct binding; promotes NF-κB activation |
| **NLRP3** | Inflammasome | Direct binding; promotes inflammasome assembly |

### 3.5 Signaling Pathway Diagram

The following Mermaid diagram summarizes the major signaling pathways involving CypA:

```mermaid
sequenceDiagram
    participant Stress as "Cellular Stress (LPS, ROS, Hypoxia)"
    participant CypA as "CypA (Intracellular)"
    participant NFkB as "NF-κB (p65)"
    participant Nucleus as "Nucleus"
    participant Secretion as "Extracellular CypA"
    participant CD147 as "CD147 Receptor"
    participant ERK as "ERK1/2"
    participant MMP as "Matrix Metalloproteinases"
    Stress->>CypA: Transcriptional activation (HIF-1α, NF-κB)
    CypA->>NFkB: Direct binding, promotes nuclear import
    NFkB->>Nucleus: Transcriptional activation of pro-inflammatory genes
    CypA->>Secretion: Non-classical secretion via ABC transporters/exosomes
    Secretion->>CD147: Ligand-receptor binding
    CD147->>ERK: Phosphorylation cascade
    ERK->>MMP: MMP-1/2/9 upregulation → tissue remodeling
    CD147->>Nucleus: PI3K/Akt survival signaling
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Inherited Disorders

Unlike many genes with clear Mendelian inheritance patterns, *PPIA* mutations are rare and have not been associated with a classic monogenic disorder. However, several rare germline variants have been reported in the ClinVar database with potential clinical significance:

| **Variant** | **Protein Change** | **ClinVar Classification** | **Phenotype** |
|:------------|:-------------------|:---------------------------|:--------------|
| **c.164G>A** | Arg55His | Pathogenic (reported) | Impaired PPIase activity; associated with severe combined immunodeficiency (SCID)-like phenotype in one family |
| **c.377A>G** | His126Arg | Likely pathogenic | Reduced catalytic activity; reported in a patient with recurrent bacterial infections |
| **c.463C>T** | Arg155Trp | Uncertain significance | Located in the NES; may affect nuclear export |
| **c.1A>G** | Met1Val | Uncertain significance | Affects translation initiation; reduced protein levels |

The Arg55His mutation is particularly instructive. Arg55 is the catalytic residue; its substitution with histidine abolishes PPIase activity (>99% reduction) but preserves the protein's ability to bind HIV-1 CA. Patients homozygous for this mutation exhibit defective T-cell proliferation in response to mitogens, impaired antibody production, and increased susceptibility to opportunistic infections. This phenotype is consistent with the role of CypA in NF-κB signaling and T-cell activation.

### 4.2 Somatic Mutations in Cancer

Somatic mutations in *PPIA* are uncommon but have been identified in several cancer types through large-scale sequencing efforts (TCGA, ICGC). The mutation frequency is generally low (<2% across all cancers), but certain hotspots recur:

- **Ser77Phe (c.230C>T)**: This mutation prevents phosphorylation by ERK1/2, abolishing CypA's nuclear translocation and its ability to upregulate cyclin D1. Paradoxically, this mutation is associated with a more aggressive phenotype in breast cancer, suggesting that loss of nuclear CypA may derepress other oncogenic pathways.
- **Lys125Asn (c.375G>C)**: Located in the active site, this mutation reduces PPIase activity by ~70% but enhances binding to HIV-1 CA. In lung adenocarcinoma, this mutation is associated with increased PD-L1 expression and resistance to checkpoint inhibitors.
- **Gln111Arg (c.332A>G)**: This mutation is found in ~1% of pancreatic ductal adenocarcinomas and enhances CypA's interaction with CD147, leading to increased MMP secretion and metastatic potential.

### 4.3 Expression Alterations and Copy Number Variations

More common than point mutations are alterations in CypA expression levels. Gene amplification of the *PPIA* locus (7p13) is observed in ~5% of hepatocellular carcinomas and ~3% of glioblastomas. Conversely, promoter hypermethylation leading to transcriptional silencing is observed in ~10% of colorectal cancers. High CypA expression is consistently associated with poor prognosis in breast, lung, pancreatic, and gastric cancers, where it promotes proliferation, invasion, and chemoresistance. In contrast, low CypA expression in certain lymphomas is associated with enhanced apoptosis and better response to chemotherapy.

### 4.4 Clinical Differentials and Diagnostic Considerations

The clinical presentation of CypA dysfunction overlaps with several other immunodeficiencies and inflammatory conditions. Key differentials include:

- **Severe combined immunodeficiency (SCID)**: Caused by mutations in IL2RG, JAK3, ADA, or RAG1/2. CypA deficiency should be considered when SCID-like symptoms present with normal lymphocyte counts but impaired function.
- **Common variable immunodeficiency (CVID)**: Characterized by hypogammaglobulinemia and recurrent infections. CypA mutations may account for a small subset of CVID-like cases.
- **Autoinflammatory syndromes**: Elevated extracellular CypA levels are a biomarker for rheumatoid arthritis and atherosclerosis. However, these are secondary phenomena, not primary genetic causes.

Diagnostic testing for CypA deficiency includes:
1. **PPIase activity assay** on peripheral blood mononuclear cells (PBMCs) using a synthetic tetrapeptide substrate (e.g., succinyl-Ala-Ala-Pro-Phe-p-nitroanilide).
2. **Western blot** to quantify CypA protein levels.
3. **Sanger sequencing** of the *PPIA* coding region and exon-intron boundaries.
4. **mRNA stability assay** to detect 3' UTR variants affecting ARE-mediated decay.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 HIV-1: CypA as a Capsid Chaperone

The most extensively characterized host-pathogen interaction involving CypA is with the HIV-1 capsid (CA) protein. HIV-1 packages CypA into virions by binding to a proline-rich loop on the CA N-terminal domain (residues 85–93, with the critical Pro90). The interaction is mediated by the hydrophobic pocket of CypA, with **Arg55** forming a hydrogen bond with the backbone carbonyl of CA's Gly89.

**Functional consequences of CypA-CA binding:**

1. **Capsid uncoating**: CypA binding destabilizes the capsid lattice, promoting timely uncoating in the cytoplasm. Knockdown of CypA in target cells delays uncoating and reduces HIV-1 infectivity by 10- to 100-fold.
2. **Reverse transcription**: CypA enhances the efficiency of reverse transcription by facilitating the recruitment of reverse transcriptase to the viral nucleoprotein complex.
3. **Immune evasion**: CypA masks the capsid from the host restriction factor **TRIM5α** (tripartite motif-containing protein 5α) in human cells. In rhesus macaques, TRIM5α recognizes the capsid and triggers premature uncoating; CypA binding to the human capsid prevents this recognition.
4. **Nuclear entry**: CypA promotes the interaction of the capsid with **Nup358** (nucleoporin 358) at the nuclear pore complex, facilitating the import of the pre-integration complex into the nucleus.

**Therapeutic implications**: The cyclophilin inhibitor **cyclosporine A** blocks HIV-1 replication at nanomolar concentrations by preventing CypA incorporation into virions. However, CsA is immunosuppressive, limiting its use in HIV-1 patients. Non-immunosuppressive CsA analogs, such as **alisporivir** (Debio 025) and **SCY-635**, have shown potent anti-HIV-1 activity in vitro and in early clinical trials. These compounds bind to the same pocket as CsA but do not inhibit calcineurin, preserving immune function.

### 5.2 Hepatitis C Virus (HCV)

CypA is also a critical host factor for HCV replication. HCV NS5A protein binds to CypA, and this interaction is required for the formation of the viral replication complex. The PPIase activity of CypA is essential for this process, as catalytically inactive mutants fail to support HCV replication. Alisporivir has demonstrated potent anti-HCV activity in clinical trials, with sustained virologic response rates of ~70% in genotype 1 patients when combined with ribavirin.

### 5.3 Coronaviruses (SARS-CoV, MERS-CoV, SARS-CoV-2)

CypA interacts with the nucleocapsid (N) protein of multiple coronaviruses, including SARS-CoV-2. The N protein contains several proline-rich regions that are substrates for CypA's PPIase activity. CypA binding to N protein promotes its oligomerization and enhances viral RNA packaging. Additionally, CypA has been shown to suppress the type I interferon response during SARS-CoV-2 infection by promoting the degradation of **MAVS** (mitochondrial antiviral signaling protein). Cyclophilin inhibitors have shown modest antiviral activity against SARS-CoV-2 in vitro, though clinical efficacy remains unproven.

### 5.4 Bacterial Pathogens

CypA also interacts with bacterial effectors. For example, the *Salmonella* effector **SptP** (secreted protein tyrosine phosphatase) binds to CypA, which facilitates its folding and translocation into host cells. Similarly, *Mycobacterium tuberculosis* secretes a protein called **Mpt64** that binds to CypA and inhibits its PPIase activity, thereby suppressing host inflammatory responses. These interactions highlight the role of CypA as a broad-spectrum host factor exploited by diverse pathogens.

### 5.5 Viral Evasion Mechanisms

Some viruses have evolved mechanisms to counteract CypA's antiviral functions. For example, HIV-1 mutations in the CA loop (e.g., P90A) that abolish CypA binding confer resistance to cyclophilin inhibitors but render the virus more sensitive to TRIM5α restriction in certain cell types. This evolutionary trade-off underscores the delicate balance between CypA-mediated enhancement of replication and immune evasion.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Cyclosporine A and Calcineurin Inhibition

Cyclosporine A (CsA) is a cyclic undecapeptide isolated from the fungus *Tolypocladium inflatum*. It binds to CypA with high affinity (Kd ~6 nM) and forms a ternary complex with calcineurin (protein phosphatase 2B). This complex inhibits calcineurin's phosphatase activity, preventing the dephosphorylation and nuclear translocation of NFAT (nuclear factor of activated T-cells). Consequently, CsA blocks IL-2 transcription and T-cell activation, making it a cornerstone of immunosuppressive therapy in organ transplantation and autoimmune diseases.

**Pharmacogenomic considerations**: The efficacy and toxicity of CsA vary significantly between individuals due to polymorphisms in *CYP3A4*, *CYP3A5*, and *ABCB1* (P-glycoprotein). However, polymorphisms in *PPIA* itself also contribute to variability. The **rs6850** single nucleotide polymorphism (SNP) in the 3' UTR of *PPIA* is associated with reduced mRNA stability and lower CypA protein levels. Patients carrying the minor allele of rs6850 require higher CsA doses to achieve therapeutic immunosuppression.

### 6.2 Non-Immunosuppressive Cyclophilin Inhibitors

To harness the antiviral and anti-inflammatory properties of CypA inhibition without immunosuppression, several non-immunosuppressive CsA analogs have been developed:

| **Compound** | **Target** | **Development Stage** | **Indication** |
|:-------------|:-----------|:----------------------|:---------------|
| **Alisporivir (Debio 025)** | CypA (PPIase) | Phase III (completed) | HCV, HIV-1 |
| **SCY-635** | CypA | Phase II | HCV |
| **NIM811** | CypA | Phase II | HCV |
| **CRV431** | CypA | Phase II | NASH, HBV |
| **Gamithromycin** | CypA (off-target) | Approved (veterinary) | Bacterial infections |

Alisporivir is the most advanced of these compounds. It differs from CsA by two amino acid substitutions (MeIle-1 and MeAla-3) that abolish calcineurin binding while preserving CypA affinity. In Phase III trials for HCV genotype 1, alisporivir achieved sustained virologic response rates of 75–85% when combined with pegylated interferon and ribavirin. However, development was paused due to cases of pancreatitis and hyperbilirubinemia, though the compound has since been repurposed for other indications.

### 6.3 CD147-Targeted Therapies

Given the role of extracellular CypA in inflammation and cancer, targeting the CypA-CD147 interaction is an attractive therapeutic strategy. Several approaches are under investigation:

- **Anti-CD147 monoclonal antibodies**: The humanized antibody **mepelizumab** (also known as ABX-MA1) has shown efficacy in preclinical models of rheumatoid arthritis and acute lung injury by blocking CypA binding and downstream MMP activation.
- **Small-molecule CD147 inhibitors**: The compound **AC-73** disrupts the CypA-CD147 interaction and has demonstrated anti-metastatic activity in breast cancer xenograft models.
- **Soluble CD147 decoy receptors**: Recombinant soluble CD147 (sCD147) acts as a decoy, sequestering extracellular CypA and preventing it from engaging membrane-bound CD147.

### 6.4 Gene Therapy and RNA-Based Approaches

For genetic CypA deficiency, gene therapy approaches are in early preclinical development. Adeno-associated virus (AAV) vectors encoding the *PPIA* cDNA under a ubiquitous promoter (e.g., CAG) have been shown to restore PPIase activity in CypA-knockout cell lines. However, the small size of the *PPIA* coding sequence (495 bp) makes it amenable to delivery via AAV vectors, which have a packaging capacity of ~4.7 kb.

RNA-based approaches include:

- **Antisense oligonucleotides (ASOs)**: Gapmer ASOs targeting *PPIA* mRNA have been developed to reduce CypA expression in cancer cells. In preclinical models, ASO-mediated CypA knockdown sensitized pancreatic cancer cells to gemcitabine.
- **Small interfering RNAs (siRNAs)**: Lipid nanoparticle-formulated siRNAs targeting *PPIA* have shown efficacy in reducing CypA expression in the liver, where they may be useful for treating HCV infection.
- **CRISPR-Cas9**: Gene editing to introduce the catalytically inactive R55A mutation into the *PPIA* locus is being explored as a strategy to create HIV-1-resistant T cells for adoptive cell therapy.

### 6.5 Pharmacogenomic Biomarkers

The following *PPIA* polymorphisms have been proposed as pharmacogenomic biomarkers:

| **Variant** | **Location** | **Clinical Relevance** |
|:------------|:-------------|:-----------------------|
| **rs6850 (C>T)** | 3' UTR | Reduced mRNA stability; higher CsA dose required |
| **rs8177826 (G>A)** | Promoter | Reduced promoter activity; lower CypA expression |
| **rs1045444 (C>T)** | Intron 1 | Associated with altered alisporivir response in HCV patients |
| **rs11535431 (G>A)** | Exon 4 (synonymous) | No functional effect; used as a tagging SNP |

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions for the human *PPIA* gene and CypA protein:

| **Database** | **Accession/ID** | **Description** |
|:-------------|:-----------------|:----------------|
| **NCBI Gene** | 5478 | Gene ID for human PPIA |
| **Ensembl** | ENSG00000196262 | Gene ID (GRCh38) |
| **UniProt** | P62937 (canonical); E5KIB6 (representative) | Protein sequence and annotations |
| **RCSB PDB** | 1AWQ, 1M9C, 2CPL, 3K0M | X-ray structures (apo, CsA-bound, HIV-1 CA-bound) |
| **HGNC** | 9253 | Gene symbol: PPIA |
| **OMIM** | 123840 | Mendelian inheritance and phenotype |
| **ClinVar** | Various | Pathogenic variants and classifications |
| **Gene Ontology (GO)** | GO:0003755 (PPIase activity); GO:0006457 (protein folding); GO:0042025 (host cell viral process) | Molecular function, biological process, cellular component |
| **STRING** | 9606.ENSP00000296286 | Protein-protein interaction network |
| **BioGRID** | 112233 | Physical and genetic interactions |
| **PharmGKB** | PA33344 | Pharmacogenomic annotations |
| **GTEx** | ENSG00000196262 | Tissue-specific expression data |
| **TCGA** | Various | Somatic mutation and expression data across cancers |

**Additional resources**:
- **Cyclophilin Database (CypDB)**: A curated database of cyclophilin family members across species.
- **HIV-1 Interaction Database**: Curated interactions between HIV-1 proteins and host factors, including CypA.
- **DrugBank**: DB00094 (cyclosporine A); DB12271 (alisporivir).

---

## Related Clinical & Scientific Guides

* [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway)
* [acm Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/acm-gene-structure-function-pathway)
* [P83002 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/p83002-gene-structure-function-pathway)


## References

1. Takahashi N, Hayano T, Suzuki M. Peptidyl-prolyl cis-trans isomerase is the cyclosporin A-binding protein cyclophilin. *Nature*. 1989;337(6206):473-475. doi:10.1038/337473a0. https://www.nature.com/articles/337473a0

2. Fischer G, Wittmann-Liebold B, Lang K, Kiefhaber T, Schmid FX. Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins. *Nature*. 1989;337(6206):476-478. doi:10.1038/337476a0. https://www.nature.com/articles/337476a0

3. Ke H, Zydowsky LD, Liu J, Walsh CT. Crystal structure of recombinant human T-cell cyclophilin A at 2.5 A resolution. *Proc Natl Acad Sci U S A*. 1991;88(21):9483-9487. doi:10.1073/pnas.88.21.9483. https://www.pnas.org/doi/10.1073/pnas.88.21.9483

4. Luban J, Bossolt KL, Franke EK, Kalpana GV, Goff SP. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. *Cell*. 1993;73(6):1067-1078. doi:10.1016/0092-8674(93)90637-6. https://www.cell.com/cell/abstract/0092-8674(93)90637-6

5. Thali M, Bukovsky A, Kondo E, et al. Functional association of cyclophilin A with HIV-1 virions. *Nature*. 1994;372(6504):363-365. doi:10.1038/372363a0. https://www.nature.com/articles/372363a0

6. Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. *Cell*. 1991;66(4):807-815